anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were treated or not treated with ICIs, and of those who benefit from immunotherapy in EGFR-mutant NSCLC.
METHODS: We analyzed patients with unresectable stage III/IV or recurrent NSCLC harboring EGFR mutations using a prospective umbrella-type lung cancer registry (CS-Lung-003).
RESULTS: A total of 303 patients who met the eligibility criteria were analyzed. The median age was 69 years; 116 patients were male, 289 had adenocarcinoma, 273 had major mutations, and 67 were treated with ICIs. The duration of EGFR-TKI treatment was longer in the Non-ICI group than in the ICI group (17.1 vs. 12.7 months, p < 0.001). Patients who received ICIs for more than 6 months were categorized into the durable clinical benefit (DCB) group (24 patients), and those who received ICIs for less than 6 months into the Non-DCB group (43 patients). The overall survival in the DCB group exhibited longer than the Non-DCB group (69.3 vs. 47.1 months), and an equivalent compared to that in the Non-ICI group (69.3 vs. 68.9 months). Multivariate analysis for time to next treatment (TTNT) of ICIs showed that a poor PS was associated with a shorter TTNT [hazard ratio (HR) 3.309; p < 0.001]. Patients who were treated with ICIs and chemotherapy combination were associated with a longer TTNT (HR 0.389; p = 0.003). In addition, minor EGFR mutation was associated with a long TTNT (HR 0.450; p = 0.046).
CONCLUSION: ICIs were administered to only 22% of patients with EGFR-mutated lung cancer, and they had shorter TTNT of EGFR-TKI compared to other patients. ICI treatment should be avoided in EGFR mutated lung cancer with poor PS but can be considered for lung cancer with EGFR minor mutations. Pathological biomarker to predict long-term responders to ICI are needed.
AIMS: Neuropathic pain remains a significant unmet medical challenge due to its elusive mechanisms. Recent clinical observations suggest that vitamin D (VitD) holds promise in pain relief, yet its precise mechanism of action is still unclear. This study explores the therapeutical role and potential mechanism of VitD3 in spared nerve injury (SNI)-induced neuropathic pain rat model.
METHODS: The analgesic effects and underlying mechanisms of VitD3 were evaluated in SNI and naïve rat models. Mechanical allodynia was assessed using the Von Frey test. Western blotting, immunofluorescence, biochemical assay, and transmission electron microscope (TEM) were employed to investigate the molecular and cellular effects of VitD3.
RESULTS: Ferroptosis was observed in the spinal cord following SNI. Intrathecal administration of VitD3, the active form of VitD, activated the vitamin D receptor (VDR), suppressed ferroptosis, and alleviated mechanical nociceptive behaviors. VitD3 treatment preserved spinal GABAergic interneurons, and its neuroprotective effects were eliminated by the ferroptosis inducer RSL3. Additionally, VitD3 mitigated aberrant mitochondrial morphology and oxidative metabolism in the spinal cord. Mechanistically, VitD3 inhibited SNI-induced activation of spinal PKCα/NOX4 signaling. Inhibition of PKCα/NOX4 signaling alleviated mechanical pain hypersensitivity, accompanied by reduced ferroptosis and mitochondrial dysfunction in SNI rats. Conversely, activation of PKCα/NOX4 signaling in naïve rats induced hyperalgesia, ferroptosis, loss of GABAergic interneurons, and mitochondrial dysfunction in the spinal cord, all of which were reversed by VitD3 treatment.
CONCLUSIONS: Our findings provide evidence that VitD3 attenuates neuropathic pain by preserving spinal GABAergic interneurons through the suppression of mitochondria-associated ferroptosis mediated by PKCα/NOX4 signaling, probably via VDR activation. VitD, alone or in combination with existing analgesics, presents an innovative therapeutic avenue for neuropathic pain.
BACKGROUND: Demographic change is leading to an increasing proportion of older people in the German population and requires new approaches for prevention and rehabilitation to promote the independence and health of older people. Technical assistance systems can offer a promising solution for the early detection of nutritional and physical deficits and the initiation of appropriate interventions. Such a system should combine different components, such as devices for assessing physical and nutritional status, educational elements on these topics, and training and feedback options. The concept is that the whole system can be used independently by older adults (aged ≥70 years) for monitoring and early detection of problems in nutrition or physical function, as well as providing opportunities for intervention.
OBJECTIVE: This study aims to develop technical and digital elements for a measurement and training station (MuTs) with an associated app. Through focus group discussions, target group requirements, barriers, and favorable components for such a system were identified.
METHODS: Older adults (aged ≥70 years) were recruited from a community-based setting as well as from a geriatric rehabilitation center. Focus group interviews were conducted between August and November 2022. Following a semistructured interview guideline, attitudes, requirements, preferences, and barriers for the MuTs were discussed. Discussions were stimulated by videos, demonstrations of measuring devices, and participants' ratings of the content presented using rankings. After conducting 1 focus group in the rehabilitation center and 2 in the community, the interview guide was refined, making a more detailed discussion of identified elements and aspects possible. The interviews were recorded, transcribed verbatim, and analyzed using content analysis.
RESULTS: A total of 21 older adults (female participants: n=11, 52%; mean age 78.5, SD 4.6 years) participated in 5 focus group discussions. There was a strong interest in the independent measurement of health parameters, such as pulse and hand grip strength, especially among people with health problems who would welcome feedback on their health development. Participants emphasized the importance of personal guidance and interaction before using the device, as well as the need for feedback mechanisms and personalized training for everyday use. Balance and coordination were mentioned as preferred training areas in a MuTs. New training options that motivate and invite people to participate could increase willingness to use the MuTs.
CONCLUSIONS: The target group is generally open and interested in tracking and optimizing diet and physical activity. A general willingness to use a MuTs independently was identified, as well as a compelling need for guidance and feedback on measurement and training to be part of the station.
INTRODUCTION: The advent of immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the management of mismatch repair deficient (MMR-d)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Initially investigated as monotherapy in phase I-II clinical trials for recurrent disease, immunotherapy demonstrated remarkable activity, yielding overall response rates (ORR) ranging from 27% to 58%. Based on these promising findings, phase III trials have explored the integration of immunotherapy into first-line treatment regimens for advanced/recurrent EC in combination with chemotherapy or other agents such as tyrosine kinase inhibitors (TKIs), resulting in improved ORR, progression-free survival, and overall survival compared to the standard chemotherapy regimen of paclitaxel and carboplatin. As a result, the incorporation of ICIs with standard platinum-based chemotherapy is becoming a new standard of care in MMR-d/MSI-H EC.
AREAS COVERED: This review synthesizes literature from PubMed, Embase databases, and recent congress abstracts on gynecological cancers. It covers MMR-d/MSI-H EC incidence, molecular diagnostics, clinical trial outcomes, predictive biomarkers for ICIs, patient profiles likely to benefit, resistance mechanisms, and the future of immunotherapy in this setting.
EXPERT OPINION: By offering a comprehensive overview, this review delineates the pivotal role of ICIs in the management of MMR-d/MSI-H EC.
The current invention lies in the field of medicine and more specifically in the field of vaccinology. The current invention concerns a novel Bordetella LPS and a modified bacterium of the genus Bordetella comprising such modified LPS. The LPS of the invention has a reduced endotoxicity in comparison to an unmodified Bordetella LPS. The modified LPS of the invention is therefore particularly suitable for use in inducing or stimulating an immune response in a subject, wherein the immune response is induced or stimulated against a Bordetella infection. The modified Bordetella LPS of the invention is obtainable by introducing in a Bordetella cell the expression of a heterologous acyl transferase. In particular, the modified Bordetella cell of the invention has an increased expression of an heterologous LpxA, LpxL or LpxD acyl transferase.
Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and clopidogrel 75mg once daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
The sexual counseling program was applied to the couples in the experimental group in 2 sessions. The "Sexual Counseling I" session which includes information about sexual life specific to the pregnancy period, was conducted at least one week later the pre-test, with face-to-face interview method in a private room in the pregnancy outpatient clinic. The "Sexual Counseling II" session, which contains information on sexual life specific to the postpartum period, was conducted online in the third trimester of pregnancy with the video interview method. Counseling sessions consisted of power point presentations (including figures and drawings) and counseling booklet. The counseling booklet prepared by the researcher in accordance with literature consisted of two parts; sexual life during pregnancy and postpartum sexual life. Each session lasted 45 minutes and additional time was allocated for answering the questions.
A pre-vaccination or pre-procedural topical anesthetic patch which functions not unlike a nicotine patch and which is essentially a round Band-Aid® (trademark) containing a topical anesthetic. The Band-Aid® anesthetic carrying device may be of any shape or size. It is applied to a persons skin at a site where a needle is to be inserted such that the site will have a topical anesthetic applied. When the Band-Aid® is removed from the site prior to a needle being inserted a visible delineation of a target area is visible on the skin. That is, that side of the Band-Aid® which contacts the skin will contain a dye, of any color, although preferably red, in the form of a circle or any other geometric shape, smaller than the diameter or size of the Band-Aid®, whereby when the Band-Aid® is removed the dye will leave a mark at the site which is the “target” area. Particularly important is the fact that once the Band-Aid® or patch is removed, prior to a needle being inserted, the target area or bull's eye or a red circle or any other color circle or geometric shape will be left on the skin which clearly delineates where the anesthetic is and, therefore, where the needle should be inserted.
Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
* Patients with RLS should take ropinirole hydrochloride tablets differently than patients with Parkinson's disease (see How should I take ropinirole hydrochloride tablets for RLS? for the recommended dosing for RLS). A lower dose of ropinirole hydrochloride is generally needed for patients with RLS, and is taken once daily before bedtime. 
  * There are known side effects of ropinirole hydrochloride.If you fall asleep or feel very sleepy while doing normal activities such as driving, faint, feel dizzy, nauseated, or sweaty when you stand up from sitting or lying down, you should talk with your doctor (see What are the possible side effects of ropinirole hydrochloride tablets?) 
  * Before starting ropinirole hydrochloride tablets, be sure to tell your doctor if you are taking any medicines that make you drowsy.




Unusual urges: Some patients taking ropinirole hydrochloride tablets get urges to behave in a way unusual for them. Examples of this are an unusual urge to gamble or increased sexual urges and behaviors. If you notice or your family notices that you are developing any unusual behaviors, talk to your healthcare provider.
Necrosis or ulceration of tumor tissue may occur during IMLYGIC treatment. Cellulitis and systemic bacterial infection have been reported in clinical studies. Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.

In clinical studies, impaired healing at the injection site has been reported. IMLYGIC may increase the risk of impaired healing in patients with underlying risk factors (e.g., previous radiation at the injection site or lesions in poorly vascularized areas). One patient had an amputation of a lower extremity 6 months after IMLYGIC injection due to an infected non-healing wound. This wound area had been treated with surgery and radiation prior to IMLYGIC treatment and had previous wound complications.

If there is persistent infection or delayed healing of the injection site(s), consider the risks and benefits of IMLYGIC before continuing treatment with IMLYGIC.
For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ. The subject invention provides methods of inactivating reactive component epitopes of moieties pathogenic substances or producing immunogenic compositions containing pathogenic substances comprising contacting pathogenic substances, or compositions containing pathogenic substances, with super critical carbon dioxide or liquid nitrogen. Similar benefits are produced using high HLB surfactants also reducing carcinogenic factors. In various embodiments, the pathogenic reactive components, epitopes, moieties or substances are inactivated and processed into immunogenic compositions. The subject invention also provides oral mucosal delivery systems for the subject therapeutic compositions and/or medications, and/or vaccines that avert the need for parenteral administration in the medical and veterinary fields.
AIMS/HYPOTHESIS: Childhood overweight increases the risk of type 2 diabetes and cardiovascular disease in adulthood. However, the impact of childhood leanness on adult obesity and disease risk has been overlooked. We examined the independent and combined influences of child and adult body size on the risk of type 2 diabetes and cardiovascular disease.
METHODS: Data from the UK Biobank on 364,695 individuals of European ancestry and free of type 2 diabetes and cardiovascular disease were divided into nine categories based on their self-reported body size at age 10 and measured BMI in adulthood. After a median follow-up of 12.8 years, 33,460 individuals had developed type 2 diabetes and/or cardiovascular disease. We used Cox regression models to assess the associations of body size categories with disease incidence.
RESULTS: Individuals with low body size in childhood and high body size in adulthood had the highest risk of type 2 diabetes (HR 4.73; 95% CI 4.50, 4.99), compared to those with average body size in both childhood and adulthood. This was significantly higher than the risk in those with high body size in both childhood and adulthood (HR 4.05; 95% CI 3.84, 4.26). By contrast, cardiovascular disease risk was determined by adult body size, irrespective of childhood body size.
CONCLUSIONS/INTERPRETATION: Low body size in childhood exacerbates the risk of type 2 diabetes associated with adult obesity but not the risk of cardiovascular disease. Thus, promoting healthy weight management from childhood to adulthood, among lean children, is crucial.
A method for mapping functionally related brain regions of a subject. The method includes receiving a structural brain image and a dataset of resting-state functional MRI (rs-fMRI) three-dimensional (3D) image frames of a brain of the subject includes 3D image frames of the subject's brain over time. A functional connectivity map identifying groupings of functionally connected voxels is overlaid on the structural brain image. Spontaneous brain activations associated with each voxel in a grouping of functionally connected voxels are time-correlated with spontaneous brain activations in one or more other voxels in the grouping of functionally connected voxels. A reference location map for a pre-defined resting state network is generated, including reference information output. The reference location map includes brain reference locations that are informative of the one or more resting-state networks to assist a user in identifying the resting state network of the functional connectivity map.
The present invention belongs to the medicine technology. The present invention particularly relates to a dispersive tablet of montelukast sodium. The dispersive tablet of montelukast sodium contains main components of montelukast sodium, disintegrating agents and auxiliary additives, wherein the disintegrating agents are common dispersive tablet type disintegrating agents used for preparing a dispersive tablet, and the auxiliary additives are common dispersive tablet type additives used for preparing a dispersive tablet. The dispersive tablet overcomes the defects that because disintegration of a montelukast sodium conventional preparation is slow, the dissolution is slow, the sufficient absorption and the therapeutic efficacy of a medicament are influenced, etc. Old patients and young patients can conveniently take the dispersive tablet. The dispersive tablet of montelukast sodium has the advantages of stable preparation, rapid absorption, high biological availability and few adverse reactions. The dispersive tablet of montelukast sodium is suitable for preventing and treating adult asthma for a long time, including preventing symptoms of asthma in a day and at night. The dispersive tablet of montelukast sodium is suitable for treating asthma of patients who are hypersensitive to aspirin and is used for preventing bronchoconstriction caused by movement, etc.
OBJECTIVE: The systemic immunity-inflammation index (SII) is a newly developed biomarker that provides an integrated measure of inflammation in the body. We aim to evaluate the relationship between SII and body fat distribution.
METHODS: Adults from the National Health and Nutrition Examination Survey (NHANES) 2011-2018 were included. The SII was computed using lymphocyte (LC), neutrophil (NC), and platelet (PC) counts as its components. Body fat distribution was assessed by (total, android, gynoid) percentage fat, total abdominal fat area, subcutaneous adipose tissue area, visceral adipose tissue area, and the ratio of visceral to subcutaneous adipose tissue area (V/S ratio). Multivariable weighted linear regression and subgroup analysis were use to examine the relationships between fat distribution and SII. Restricted cubic splines (RCS) and threshold effect analysis were used to examine analyze nonlinear associations.
RESULTS: After exclusions, a total of 11,192 adults with a weighted mean age of 38.46 ± 0.26 years were studied. In multivariable weighted linear regression, each level increase in log2SII was associated with increased of 0.23 SDs total percentage fat (95% CI = 0.03, 0.43) and 0.26 SDs android percentage fat (95% CI = 0.06, 0.47). Besides, the subgroup analysis showed that the positive association between SII and android percentage fat was mainly among obese individuals (BMI > 30 kg/m2) and non-obese individuals without DM or hypertension. Meanwhile, the relationship between SII and the V/S ratio was found to be significant in the female subgroup, the obese subgroup, individuals with non-alcoholic fatty liver disease (NAFLD), and those without diabetes mellitus. Finally, SII exhibited an inverted U-shaped relationship with total percentage fat, android percent fat and total abdominal fat. Accordingly, threshold effect analysis indicated a positive association between lower SII levels and total percentage fat, android percentage fat and total abdominal fat area.
CONCLUSIONS: In the nationwide study, it was observed that the SII exhibited a significant correlation with higher levels of body fat, specifically android fat. This association was particularly noticeable within specific subgroups of the population.
The present invention relates to a skin-whitening composition containing paper mulberry extracts, more specifically containing extracts from Acer barbinerve Maxim, Acer barbinerve var. glabrescens, Wikstroemia trichotoma (Thunb.) Makino, Acer komarovii Pojark, Edgeworthia chrysantha Lindl. Broussonetia papyrifera for. oppositifolia Nakai, Broussonetia papyrifera for. Lucida (Hatus) T.B. Lee, Daphne pseudomezereum var. koreana (Nakai) Hamaya, or Broussonetia kazinoki Siebold, and thereby enables safe usage on skin without side effects, and inhibition of discoloration by suppressing melanin formation.
The application provides a VEGF-trap polypeptide and application thereof. The VEGF-trap polypeptides described herein comprise an amino acid substitution at position 148 as compared to the sequence set forth in SEQ ID No. 8. The VEGF-trap polypeptides described herein comprise a mutant of the second Ig domain of VEGFR1 and the third Ig domain of VEGFR 2. The VEGF-trap described herein can be used to construct fusion proteins or immunoconjugates. The application also provides the use of the VEGF-trap or fusion protein or immunoconjugate in the treatment of a disease or disorder.